Key Details
Price
$88.35Annual Revenue
$249.38 MAnnual EPS
-$8.37Annual ROE
-157.13%Beta
1.44Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Blueprint Medicines' main source of income, AYVAKIT, is becoming popular for treating systemic mastocytosis and gastrointestinal stromal tumors, showing good market acceptance. The recent launch of AYVAKIT in Germany and the possibility of expanding its uses support Blueprint's value and future revenue expectations. Additionally, Blueprint's research pipeline, which includes drugs like BLU-222 and elenestinib, aims at different cancers and mast cell disorders, boosting its long-term growth prospects.
Blueprint's stock has increased due to stronger-than-anticipated results for the third quarter, mainly because of significant growth in Ayvakit sales. The company has also updated its revenue forecast for 2024.
Blueprint Medicines Corporation (NASDAQ:BPMC) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 8:00 AM ET. The call will feature several company executives, including CEO Kate Haviland and CFO Mike Landsittel, along with various participants from financial institutions. The operator for the call is Nadia, who will assist with the proceedings.
Blueprint Medicines (BPMC) reported a quarterly loss of $0.89 per share, which is better than the Zacks Consensus Estimate of a $0.97 loss. This is an improvement compared to a loss of $2.20 per share from the same period last year.
In the third quarter of 2024, Blueprint Medicines Corporation reported net product revenues of $128.2 million from AYVAKIT. They have increased their revenue forecast for AYVAKIT to between $475 million and $480 million for the year. Additionally, they are on track to start the HARBOR Part 2 study of elenestinib for ISM by the end of the year.
The approval of new drugs and advancements in research are expected to keep the Zacks Biomedical and Genetics industry moving forward. Companies like EXEL, BPMC, CRSP, FOLD, and VRNA have a strong range of products and promising research, which puts them in a good position in this unpredictable market.
Blueprint Medicines (BPMC) lacks the necessary combination of two important factors that could lead to a strong earnings report in the near future. Be ready for the main expectations.
Blueprint Medicines (BPMC) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #1 (Strong Buy).
CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) has announced that it will hold a live conference call and webcast at 8:00 a.m.
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national firm that represents shareholders, is looking into claims for investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) regarding possible violations of securities laws. The investigation is centered on whether the Company made false or misleading statements and/or did not share important information with investors.
FAQ
- What is the primary business of Blueprint Medicines?
- What is the ticker symbol for Blueprint Medicines?
- Does Blueprint Medicines pay dividends?
- What sector is Blueprint Medicines in?
- What industry is Blueprint Medicines in?
- What country is Blueprint Medicines based in?
- When did Blueprint Medicines go public?
- Is Blueprint Medicines in the S&P 500?
- Is Blueprint Medicines in the NASDAQ 100?
- Is Blueprint Medicines in the Dow Jones?
- When was Blueprint Medicines's last earnings report?
- When does Blueprint Medicines report earnings?
- Should I buy Blueprint Medicines stock now?